TAK-071

DRUG3 trials

Sponsors

Takeda

Conditions

Alzheimer DiseaseHealthy ParticipantsHealthy VolunteersParkinson Disease

Phase 1

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

TerminatedNCT02769065

TakedaAlzheimer Disease, Healthy Volunteers

Start: 2016-05-05End: 2017-06-08Updated: 2019-06-10

TAK-071 Scopolamine-Induced Cognitive Impairment Study

TerminatedNCT02918266

TakedaHealthy Volunteers

Start: 2016-11-21End: 2017-08-08Updated: 2019-06-14

Phase 2

A Study of TAK-071 in People With Parkinson Disease

CompletedNCT04334317

TakedaHealthy Participants, Parkinson Disease

Start: 2020-10-21End: 2023-02-27Updated: 2024-05-14

Related Papers

An Acetylcholine M<sub>1</sub> Receptor–Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment

JAMA Neurology2025-01-0618 citations

[P2–051]: <i>IN VITRO</i> CHARACTERIZATION OF TAK‐071: A NOVEL MUSCARINIC M<sub>1</sub> RECEPTOR‐POSITIVE ALLOSTERIC MODULATOR WITH LOW COOPERATIVITY

Alzheimer s & Dementia2017-07-012 citations

[P2–048]: AN APPROACH TO DISCOVER NOVEL MUSCARINIC M<sub>1</sub> RECEPTOR‐POSITIVE ALLOSTERIC MODULATORS WITH POTENT COGNITIVE IMPROVEMENT AND MINIMIZED GASTROINTESTINAL DYSFUNCTION

Alzheimer s & Dementia2017-07-011 citations